Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer: An Observational Study
Status: Recruiting
Location: See all (2) locations...
Intervention Type: Drug
Study Type: Observational
SUMMARY
This is an observational, retrospective/prospective, multicenter study designed to define, overall survival, clinical outcomes and predictive/prognostic factors of a consecutive population of mCRPC patients treated with olaparib in clinical practice.
Eligibility
Participation Requirements
Sex: Male
Healthy Volunteers: f
View:
• BRCA mutant Metastatic castration-resistant prostate cancer patients treatment with olaparib in clinical practice
Locations
Other Locations
Italy
Sabrina Rossetti
RECRUITING
Napoli
Orazio Caffo
RECRUITING
Trento
Contact Information
Primary
Orazio Caffo, MD
orazio.caffo@apss.tn.it
+390461902478
Time Frame
Start Date: 2023-01-01
Estimated Completion Date: 2026-12-31
Participants
Target number of participants: 3000
Treatments
mCRPC treated with olaparib
mCRPC patients who receive olaparib in daily clinical practice
Related Therapeutic Areas
Sponsors
Leads: Santa Chiara Hospital